Maximum Standardized Uptake Value and Cell-Free DNA to Predict Adjuvant Therapy in Resectable NonSmall Cell Lung Cancer

被引：0
|
作者：
Azkona Uribelarrea, E. [1 ]
Aurrekoetxea Oribe, J. [1 ]
Portilla-Quattrociocchi, H. [1 ]
Casas, R. [1 ]
Ortega Gallastegi, B. [1 ]
Calvo Martinez, M. B. [1 ]
机构：
[1] Cruces Univ Hosp, Baracaldo, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
maxSUV; cfDNA; adjuvant therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07G.05
引用
收藏
页码：S561 / S561
页数：1
相关论文
共 50 条
  • [1] Maximum Standard Uptake Lean Body Mass (SULmax) [18F] FDG PET/CT and Cell-Free DNA to Predict Adjuvant Therapy requirements in Resectable Non-Small Cell Lung Cancer (NSCLC)
    Portilla Quattrociocchi, H.
    Azkona Uribelarrea, E.
    Aurrekoetxea Oribe, J.
    Calvo Martinez, M.
    Nunez-Munoz, R.
    Jimenez-Alonso, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S500 - S500
  • [2] Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer
    Waki, Kayoko
    Yokomizo, Kanako
    Yoshiyama, Koichi
    Takamori, Shinzo
    Komatsu, Nobukazu
    Yamada, Akira
    IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2021, 43 (02) : 176 - 182
  • [3] Adjuvant therapy of operable nonsmall cell lung cancer: an update
    Mitsudomi, Tetsuya
    Soh, Junichi
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (01) : 47 - 54
  • [4] A correlation study between maximum standardized uptake values and pathology and clinical staging in nonsmall cell lung cancer
    Lu, Peiou
    Yu, Lijuan
    Li, Yingci
    Sun, Yajuan
    NUCLEAR MEDICINE COMMUNICATIONS, 2010, 31 (07) : 646 - 651
  • [5] Prognostic value of FDG uptake in nonsmall cell lung cancer.
    Park, JM
    Choi, JY
    Lee, KH
    Choi, Y
    Choe, YS
    Kim, SE
    Kim, BT
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 297P - 297P
  • [6] Clinically Predictive Value of Plasma Cell-Free DNA in Lung Cancer Immunotherapy
    Yu, J.
    Zhou, Z.
    Zhang, P.
    Li, P.
    Tang, M.
    Fang, N.
    Wu, X.
    Nie, X.
    Guan, Y.
    Xia, X.
    Yang, L.
    Yi, X.
    Li, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S331 - S332
  • [7] A Sight of the Diagnostic Value of Aberrant Cell-Free DNA Methylation in Lung Cancer
    Zhao, Hui
    Zhang, Hui
    Xu, Wei
    Wen, Baiqing
    Kang, Yani
    DISEASE MARKERS, 2022, 2022
  • [8] Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer
    Shyr, Bor-Uei
    Shyr, Bor-Shiuan
    Chen, Shih-Chin
    Chang, Shih-Ching
    Shyr, Yi-Ming
    Wang, Shin-E
    CANCERS, 2021, 13 (10)
  • [9] Surgically resectable nonsmall cell lung cancer: a contemporary approach
    D'Amours, Marie-Frederique
    Wu, Florence T. H.
    Theisen-Lauk, Olivia
    Chan, Elisa K.
    McGuire, Anna
    Ho, Cheryl
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64 (02)
  • [10] POSTOPERATIVE ADJUVANT THERAPY FOR NONSMALL CELL LUNG-CANCER - A CONSENSUS REPORT
    IHDE, D
    BALL, D
    ARRIAGADA, R
    BARTHELEMY, N
    BENNER, S
    BONNER, J
    BUREAU, G
    CRINO, L
    DENEFFE, G
    EMAMI, B
    FELD, R
    JOSEPH, D
    PACCAGNELLA, A
    ROCMANS, P
    VANHOUTTE, P
    LUNG CANCER, 1994, 11 : S15 - S17
12345